Understanding how certain signals in the brain can reduce seizures
Molecular Pathways that Strengthen GABAergic Inhibition and Reduce Seizure Susceptibility
This study is looking at how a specific signaling pathway in the brain affects nerve cell activity, especially in people with epilepsy, to find new ways to improve brain function and reduce seizures.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11128844 on NIH RePORTER |
What this research studies
This research investigates the role of FLT3 signaling in regulating neuronal function and excitability in both healthy and epileptic brains. By focusing on the chloride transporter KCC2, which is crucial for GABAergic inhibition, the study aims to identify new drug interventions that can enhance this inhibition and potentially reduce seizure susceptibility. The approach includes using specialized mouse models to explore the effects of FLT3 on neuronal signaling and its implications for brain disorders. Patients may benefit from insights that could lead to novel treatments for epilepsy and related conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 21 and older who experience epilepsy or related neurological disorders.
Not a fit: Patients with seizure disorders that are not responsive to GABAergic modulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce seizure occurrences in patients with epilepsy.
How similar studies have performed: Previous research has shown promising results in enhancing GABAergic inhibition through targeted signaling pathways, indicating potential for success in this novel approach.
Where this research is happening
Boston, United States
- Boston Children's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Tang, Xin — Boston Children's Hospital
- Study coordinator: Tang, Xin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.